Successful pulmonary clearance of the encapsulated yeast Cryptococcus neoformans
requires a T1 adaptive immune response. This response takes up to 3 weeks to fully …

We evaluated cell-mediated immune (CMI) responses in mice given a pulmonary infection
with a Cryptococcus neoformans strain engineered to produce the Th1-type cytokine gamma …

Cryptococcus neoformans is a major etiological agent of fungal meningoencephalitis. The
outcome of cryptococcosis depends on the complex interactions between the pathogenic …

Cryptococcus species are encapsulated fungi found in the environment that predominantly
cause disease in immunocompromised hosts after inhalation into the lungs. Even with …

Cryptococcosis, caused by Cryptococcus neoformans, has been demonstrated to be
controlled by T helper (Th) 1 cells while Th2 cells are associated with fungal growth and …

Cryptococcus neoformans was first described as a human fungal pathogen more than a
century ago. One aspect of the C. neoformans infectious life cycle that has been the subject …

The immune response to Cryptococcus neoformans following pulmonary infection of
C57BL/6 wild-type (WT) mice results in the development of persistent infection with …

The major capsular polysaccharide of Cryptococcus neoformans, glucuronoxylomannan
(GXM), is recognized by Toll-like receptor 2 (TLR2), TLR4, and CD14. In these studies, mice …

This chapter focuses on the dynamic interaction of Cryptococcus neoformans with alveolar
macrophages (AMs) and how the consequential actions of both the host and fungal …

Cryptococcus neoformans is a major cause of fungal pneumonia, meningitis and
disseminated disease in the immune compromised host. Here we have used a clinically …